GlassScriptPhysician profile
Sydney L Egan
NPI 1396203758
$13,639.65
in general payments reported to CMS, 2019-2025
29 companies · $2,195 in 2025
The $2,195 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,269 · 2022: $3,499 · 2023: $3,195 · 2024: $2,482 · 2025: $2,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,860 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,859.79 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,826.56 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,553.76 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,456.20 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Supernus Pharmaceuticals, INC. | $1,292.70 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,253.63 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,252.01 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,154.90 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $558.15 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $412.88 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $412.62 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $374.26 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $364.24 | 2021-2025 | Rexulti |
| Corium, LLC | $291.73 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $246.53 | 2022-2025 | Fanapt |
| Almatica Pharma LLC | $233.77 | 2021-2024 | Loreev Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $221.37 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $213.64 | 2021-2022 | |
| Eisai INC. | $114.84 | 2021 | |
| Bausch Health US, LLC | $80.19 | 2022-2023 | Aplenzin |
| Neuronetics, INC. | $64.15 | 2022-2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $51.26 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $42.33 | 2024 | |
| Collegium Pharmaceutical, INC. | $33.14 | 2025 | Jornay Pm |
| Tris Pharma INC | $31.89 | 2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $26.63 | 2023 | Belsomra |
| Tempus Ai, INC | $25.17 | 2024 | |
| Alfasigma USA, INC. | $24.21 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.92 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sydney Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.